Switching to TDF-FTC from ABC-3TC for Hyperlipidemia **ROCKET II**



Switching to TDF-FTC from ABC-3TC for Hyperlipidemia ROCKET II: Study Design

Study Design: ROCKET II

• **Background**: Randomized, controlled, 12-week, phase IV trial to assess the effect on lipid profile of switching from abacavir-lamivudine plus lopinavir-ritonavir to tenofovir-emtricitabine plus lopinavir-ritonavir in patients with HIV infection and hyperlipidemia

Inclusion Criteria (n = 85)

- Age ≥18
- HIV RNA <50 copies/mL for ≥12 weeks
- Stable ART with ABC, 3TC, and LPV-RTV ≥24 weeks
- Fasting total cholesterol ≥200 mg/dL on two tests ≥4 weeks apart
- Treatment Arms
 - TDF-FTC 300-200 mg QD + Lopinavir-ritonavir 200/50 mg as prescribed
 - ABC-3TC 600-300 mg QD + Lopinavir-ritonavir 200/50 mg as prescribed





Switching to TDF-FTC from ABC-3TC for Hyperlipidemia ROCKET II: Results

Week 12: Virologic Response (ITT, Missing=Failure)





Switching to TDF-FTC from ABC-3TC for Hyperlipidemia ROCKET II: Results

Week 12: Analysis of Fasting Lipids





Switching to TDF-FTC from ABC-3TC for Hyperlipidemia ROCKET II: Conclusions

Conclusions: "Switching to TDF/FTC from ABC/3TC was associated with rapid improvements in fasting lipid parameters and continued virological control in patients receiving LPV/r as the third component of antiretroviral therapy. The effect of these changes on clinical end points remains unclear and would need to be evaluated in a longer-term study."



Acknowledgment

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.



